DUBLIN, May 28, 2024--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.
Celebrations may be in order for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, with the analysts delivering a...
The analysts might have been a bit too bullish on Prothena Corporation plc ( NASDAQ:PRTA ), given that the company fell...